Pfizer Inc. (PFE)'s Experimental Drug Works in Ulcerative Colitis  
8/16/2012 6:43:21 AM

Pfizer Inc. (PFE)’s experimental rheumatoid arthritis pill tofacitinib eased symptoms of patients with ulcerative colitis, an inflammatory bowel disease that affects 750,000 Americans, a company-sponsored study showed. Among 194 adults with moderate to severe ulcerative colitis, tofacitinib reduced symptoms such as pain and bleeding in 78 percent of patients given the trial’s highest dose, according to results published in the New England Journal of Medicine. The study was from the second of three stages of human tests needed for regulatory approval.